Factors that affect the duration of the interval between the completion of palliative chemotherapy and death

Oncologist

Volumn 14, Issue 7, 2009, Pages 752-759

  Hashimoto, Kenji ^a   Yonemori, K A N ^a   Katsumata, Noriyuki ^a   Hotchi, Marika ^b   Kouno, Tsutomu ^a   Shimizu, Chikako ^a   Tamura, Kenji ^a   Ando, Masashi ^a   Takeuchi, Masahiro ^b   Fujiwara, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Best supportive care; Death; End of life; Palliative chemotherapy; Survival

Indexed keywords

ARTICLE; CLINICAL PRACTICE; DEATH; GYNECOLOGIC CANCER; HEALTH SURVEY; HUMAN; MEDICAL LITERATURE; PALLIATIVE THERAPY; PHYSICIAN; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; PALLIATIVE CARE; QUALITY OF LIFE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 68449089673     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0257     Document Type: Article

References (22)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002.CA Cancer J Clin 2005;55:74-108.
2. Earle CC, Neville BA, Landrum MB et al. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2004;22:315-321. (Pubitemid 41095097)
3. Glare P, Virik K, Jones M et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ 2003;327:195-198.
4. Panagopoulou E, Mintziori G, Montgomery A et al. Concealment of information in clinical practice: Is lying less stressful than telling the truth? J Clin Oncol 2008;26:1175-1177.
5. Matsuyama R, Reddy S, Smith TJ. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 2006;24:3490-3496. (Pubitemid 46638908)
6. Koedoot CG, De Haes JC, Heisterkamp SH et al. Palliative chemotherapy or watchful waiting? A vignettes study among oncologists. J Clin Oncol 2002;20:3658-3664.
7. Sahm S, Will R, Hommel G. What are cancer patients' preferences about treatment at the end of life, and who should start talking about it? A comparison with healthy people and medical staff. Support Care Cancer 2005; 13:206-214. (Pubitemid 40576506)
8. McNiff KK, Neuss MN, Jacobson JO et al. Measuring supportive care in medical oncology practice: Lessons learned from the quality oncology practice initiative. J Clin Oncol 2008;26:3832-3837.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
10. Grunfeld EA, Ramirez AJ, Maher EJ et al. Chemotherapy for advanced breast cancer: What influences oncologists' decision-making? Br J Cancer 2001;84:1172-1178.
11. Porzsolt F, Tannock I. Goals of palliative chemotherapy. J Clin Oncol 1993;11:378-381.
12. Weeks JC, Cook EF, O'Day SJ et al. Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA 1998;279: 1709-1714. (Pubitemid 28247301)
13. Balmer CE, Thomas P, Osborne RJ. Who wants second-line, palliative chemotherapy? Psychooncology 2001;10:410-418. (Pubitemid 32904005)
14. Grunfeld EA, Maher EJ, Browne S et al. Advanced breast cancer patients' perceptions of decision making for palliative chemotherapy. J Clin Oncol 2006;24:1090-1098. (Pubitemid 46638806)
15. Earle CC, Landrum MB, Souza JM et al. Aggressiveness of cancer care near the end of life: Is it a quality-of-care issue? J Clin Oncol 2008;26: 3860-3866.
16. Koedoot CG, Oort FJ, de Haan RJ et al. The content and amount of information given by medical oncologists when telling patients with advanced cancer what their treatment options are: Palliative chemotherapy and watchful-waiting. Eur J Cancer 2004;40:225-235.
17. Sullivan AM, Lakoma MD, Matsuyama RK et al. Diagnosis and discussing imminent death in the hospital: A secondary analysis of physician interviews. J Palliat Med 2007;10:882-893.
18. Reck M. Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC). Anticancer Res 2005;25:1501-1506. (Pubitemid 40896755)
19. Rocconi RP, Case AS, Straughn JM Jr et al. Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis. Cancer 2006;107:536-543. (Pubitemid 44107214)
20. Glimelius B, Hoffman K, Graf W et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995;6:267-274.
21. Connor SR, Pyenson B, Fitch K et al. Comparing hospice and nonhospice patient survival among patients who die within a three-year window. J Pain Symptom Manage 2007;33:238-246. (Pubitemid 46349540)
22. Cancer control knowledge into action. WHOGuide for Effective Programs. Palliative Care. 2007.